Pharmacon Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 14-12-2024
- Paid Up Capital ₹ 0.15 M
as on 14-12-2024
- Company Age 11 Year, 5 Months
- Last Filing with ROC 31 Mar 2020
- Revenue -98.66%
(FY 2020)
- Profit -59712.59%
(FY 2020)
- Ebitda 65.69%
(FY 2020)
- Net Worth -93.70%
(FY 2020)
- Total Assets -61.55%
(FY 2020)
About Pharmacon Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.15 M, as per Ministry of Corporate Affairs (MCA) records.
Nasrin Ahmed and Mohd Uddin serve as directors at the Company.
- CIN/LLPIN
U52100MH2013PTC246052
- Company No.
246052
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jul 2013
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Pharmacon Biotech Private Limited offer?
Pharmacon Biotech Private Limited offers a wide range of products and services, including Antifungal Injection, Tablet & Syrup, Itraconazole Capsule and Tablet, Pharmaceutical Syrup, Pharmaceutical Medicine, Pharmaceutical Drug.
Who are the key members and board of directors at Pharmacon Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nasrin Ahmed  | Director | 23-Jul-2013 | Current |
| Mohd Uddin | Director | 20-Mar-2014 | Current |
Financial Performance of Pharmacon Biotech.
Pharmacon Biotech Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 98.66% decrease. The company also saw a substantial fall in profitability, with a 59712.59% decrease in profit. The company's net worth observed a substantial decline by a decrease of 93.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pharmacon Biotech?
In 2020, Pharmacon Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pharmacon Lifecure Solutions LlpActive 2 years 8 monthsNasrin Ahmed and Mohd Uddin are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Pharmacon Biotech?
Unlock and access historical data on people associated with Pharmacon Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pharmacon Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pharmacon Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
